Compounds > paris saponin vii
Page last updated: 2024-11-08

paris saponin vii

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Paris saponin VII: has antineoplastic activity; isolated from Trillium tschonoskii; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
TrilliumgenusA plant genus of the family Melanthiaceae that is a short plant with a distinct whorl of 3 broad leaves.[MeSH]MelanthiaceaeA family in the order Liliales, of bulbous or rhizomatous woodland and alpine perennial herbs.[MeSH]

Cross-References

ID SourceID
PubMed CID176233
MeSH IDM000604204

Synonyms (15)

Synonym
pennogenin tetraglycoside
68124-04-9
S9156
beta-d-glucopyranoside, (3beta,25r)-17-hydroxyspirost-5-en-3-yl o-6-deoxy-alpha-l-mannopyranosyl-(1-2)-o-(o-6-deoxy-alpha-l-mannopyranosyl-(1-4)-6-deoxy-alpha-l-mannopyranosyl-(1-4))-
chonglou saponin vii
dioscinin
AKOS032946455
paris saponin-vii
BS-14117
CS-0023885
paris saponin vii
HY-N3584
CCG-270613
paris vii
DTXSID101318576
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (5.56)18.7374
1990's0 (0.00)18.2507
2000's1 (5.56)29.6817
2010's8 (44.44)24.3611
2020's8 (44.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.82 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index5.77 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
2,3,4,5-tetrahydroxypentanal
[no description available]		2.3110hydroxyaldehyde;
pentose;
polyol
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		2.1310azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
tricalcium phosphate
tricalcium phosphate: a form of tricalcium phosphate used as bioceramic bone replacement material; see also records for alpha-tricalcium phosphate, beta-tricalcium phosphate, calcium phosphate; apatitic tricalcium phosphate Ca9(HPO4)(PO4)5(OH) is the calcium orthophosphate leading to beta tricalcium phosphate Ca3(PO4)2 (b-TCP). calcium phosphate : A calcium salt composed of calcium and phosphate/diphosphate ions; present in milk and used for the mineralisation of calcified tissues.		2.3110calcium phosphate
diosgenin
[no description available]		2.13103beta-sterol;
hexacyclic triterpenoid;
sapogenin;
spiroketal		antineoplastic agent;
antiviral agent;
apoptosis inducer;
metabolite
gefitinib
[no description available]		2.1310aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
inositol 1,4,5-trisphosphate
Inositol 1,4,5-Trisphosphate: Intracellular messenger formed by the action of phospholipase C on phosphatidylinositol 4,5-bisphosphate, which is one of the phospholipids that make up the cell membrane. Inositol 1,4,5-trisphosphate is released into the cytoplasm where it releases calcium ions from internal stores within the cell's endoplasmic reticulum. These calcium ions stimulate the activity of B kinase or calmodulin.		2.0710myo-inositol trisphosphatemouse metabolite
pectins
Pectins: High molecular weight polysaccharides present in the cell walls of all plants. Pectins cement cell walls together. They are used as emulsifiers and stabilizers in the food industry. They have been tried for a variety of therapeutic uses including as antidiarrheals, where they are now generally considered ineffective, and in the treatment of hypercholesterolemia.. alpha-D-galacturonic acid : The alpha-anomer of D-galacturonic acid.		2.3110D-galactopyranuronic acid
glycosides
[no description available]		2.0410
beta-escin
[no description available]		4.2140
formosanin c
formosanin C: diosgenin saponin from Paris formosana; structure given in first source		2.1310
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		07.6920
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.6920
Cancer of Colon
[description not available]		02.3110
Colonic Neoplasms
Tumors or cancer of the COLON.		02.3110
Carcinoma, Non-Small Cell Lung
[description not available]		02.6920
Cancer of Lung
[description not available]		02.930
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		02.6920
Lung Neoplasms
Tumors or cancer of the LUNG.		02.930
Di Guglielmo Disease
[description not available]		02.3110
Leukemia, Erythroblastic, Acute
A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.		02.3110
Colorectal Cancer
[description not available]		07.2110
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.2110
Lung Adenocarcinoma
[description not available]		02.1310
Adenocarcinoma, Basal Cell
[description not available]		02.1310
Adenocarcinoma of Lung
A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.		02.1310
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.1310
Bone Cancer
[description not available]		02.1310
Osteogenic Sarcoma
[description not available]		02.1310
Invasiveness, Neoplasm
[description not available]		02.1310
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.		02.1310
Osteosarcoma
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)		07.1310